+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
28 Apr 2017

EpiVax licenses novel immune-modulating technology to a global pharmaceutical company (undisclosed)

EpiVax, a Providence-based biotechnology company, has licensed its novel immune-modulating technology to an undisclosed global pharmaceutical company, for use in autoimmune disease and allergy.

Tregitopes are a set of peptides first discovered in human immunoglobulin by EpiVax chief executive officer Annie De Groot and EpiVax chief information officer Bill Martin. Similar to intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes are capable of engaging regulatory T cells, the human body’s natural “off switch” for inflammation.

In vivo studies in animals have described the immune-modulating effect of Tregitopes as safe and antigen-specific (De Groot, 2008, doi:10.1182/blood-2008-02-138073). Activation and engagement of regulatory T cells is important in autoimmune diseases such as Systemic Lupus Erythematosis (SLE), Chrohn’s disease, Rheumatoid Arthritis and allergy.

The undisclosed company has taken a non-exclusive license to apply EpiVax’s novel Tregitope technology to ameliorate human autoimmune diseases and allergy. The licensee will enjoy a worldwide commercial license to enhance their in-house therapeutic development strategy for allergy and autoimmunity. Other routes of administration, modes of delivery, and applications of Tregitope remain proprietary and exclusive to EpiVax.


KPE’s Executive Program in Pharmaceutical Global Business

1000+ Case Studies, 100s of e-lectures, simulation based learning. Ideal for Top and Middle Level managers in Pharma and Bio-Pharma organization.

View Course Content


KPE-C-022 – KPE’s Certificate Program in Biologic (Biotech and Biosimilar) Regulation & Strategic 

View Course Content

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.